Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Radiprodil is an antagonist of NR2B subunit-containing NMDA receptors (IC50 = 8 nM).1 It is selective for NR2B subunit-containing NMDA receptors over NR1 and NR2A subunit-containing NMDA receptors at 15 µM. Radiprodil (10 nM) reduces amyloid β (1-42) (Aβ42) and Aβ40-induced decreases in dendritic spine density in mouse hippocampal CA1 pyramidal neurons.2 Radiprodil (2 mg/kg) restores novel object-stimulated locomotion in a marmoset model of MPTP-induced Parkinson's disease.3
WARNING This product is not for human or veterinary use.
1. Oxamides as novel NR2B selective NMDA receptor antagonists. Bioorg. Med. Chem. Lett. 14(15), 3953-3956 (2004).
2. The NMDA receptor antagonist radiprodil reverses the synaptotoxic effects of different amyloid-
3. Antiparkinsonian effects of the "Radiprodil and Tozadenant" combination in MPTP-